MedTrace Logo

Semen Analysis Parameters Following Pfizer's COVID-19 Vaccine

NCT04778033 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2021-03-02

No results posted yet for this study

Summary

In this study the investigators will explore the effect of the BNT162b2 COVID-19 Vaccine on semen analysis parameters among 75 fertile men. Fertile men will be regarded as such if they previously successfully impregnated their partners without the use of artificial reproductive technology, or men who previously had a normal sperm analysis exam by WHO criteria (2010). Those recruited will supply a single sperm sample 1-2 months following the second dose of the vaccination. In addition, the participants will fill a brief questionnaire with information regarding their medical and reproductive history. The investigators will examine the macroscopic and microscopic properties of the semen samples and compare them to the WHO semen analysis reference range in an attempt to ascertain whether the vaccine influences sperm parameters.

Conditions

  • Covid19
  • Fertility Issues

Interventions

OTHER

Sperm collection

Those recruited will supply a single sperm sample 1-2 months following the second dose of the vaccination. The sample will be analyzed for macroscopic and microscopic features in the IVF laboratory and will be discarded immediately afterwards.

Sponsors & Collaborators

  • Sheba Medical Center

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-09
Primary Completion
2021-04-10
Completion
2021-05-01

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04778033 on ClinicalTrials.gov